search
Back to results

Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype

Primary Purpose

Asthma

Status
Unknown status
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Bronchial Thermoplasty
Sponsored by
National University Hospital, Singapore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Bronchial Thermoplasty

Eligibility Criteria

21 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females between 21-65 years of age
  • Poorly controlled severe persistent asthma (ACT score < 20) despite high-dose inhaled steroids (>500 mcg fluticasone/day or >800 mcg budesonide/day) in combination with inhaled long-acting Beta-2 agonist and/or anticholinergic agent. Other drugs include leukotriene modifiers, omalizumab (if used for at least 1 year prior), and oral corticosteroids 10mg/day or less
  • Stopped smoking for > 1 year and <10 pack-years
  • Stable maintenance asthma medications for 4 weeks
  • Pre-bronchodilator FEV1 >60% predicted

Exclusion Criteria:

  • Males and females <21 and >65 years of age
  • Presence of pacemaker, internal defibrillator, or other implantable electronic devices
  • Known sensitivity to medications required to perform bronchoscopy, including lignocaine and benzodiazepines
  • Patients previously treated with Bronchial Thermoplasty (BT)
  • Use of immunosuppressant (excluding oral steroids)
  • Increased risk of adverse events associated with bronchoscopy or anesthesia (including pregnancy, uncontrolled coronary artery disease, acute or chronic renal failure, and uncontrolled hypertension)
  • Inability to cease antiplatelet or anticoagulant therapy prior to procedure

Sites / Locations

  • National University Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Bronchial Thermoplasty

Arm Description

Bronchial thermoplasty

Outcomes

Primary Outcome Measures

Asthma Control Test (ACT) score

Secondary Outcome Measures

Percentage of symptom-free days
Number of adverse events
Peak Expiratory Flow (PEF)
Exhaled nitric oxide (NO)
Forced Expiratory Volume in 1 Second (FEV1)
Non-contrast Computed Tomography (CT) scan of the thorax

Full Information

First Posted
February 13, 2014
Last Updated
February 26, 2014
Sponsor
National University Hospital, Singapore
search

1. Study Identification

Unique Protocol Identification Number
NCT02075151
Brief Title
Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype
Official Title
Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Unknown status
Study Start Date
February 2014 (undefined)
Primary Completion Date
May 2018 (Anticipated)
Study Completion Date
May 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National University Hospital, Singapore

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
According to World Health Organization (WHO) estimates, more than 200 million people suffer from asthma worldwide and in 2009, the disease had claimed 250,000 lives globally. Autopsy reports suggest 2 phenotypes of severe asthma: one that is characterized by intense airway inflammation with mucus plugging, and the other by severe bronchoconstriction causing respiratory failure in the absence of significant airway inflammation. However, it is not easy to stratify patients according to phenotypes without bronchoscopy. Although severe asthma comprises only 10% of affected individuals, it accounts for more than half of the total healthcare spending on asthma. Inhaled corticosteroids are effective by suppressing production of multiple pro-inflammatory mediators, unfortunately efficacy plateaus. Addition of long acting beta agonist and anti-cholinergic agent to inhaled corticosteroids offers some measure of relief but effective treatment of severe asthma remains an unmet goal, resulting in intensive utilization of healthcare resources. In 2010, the United States Food and Drug Administration (FDA) approved bronchial thermoplasty (BT) as an adjunctive therapy for severe asthma. BT is radiofrequency ablation of airway smooth muscle via bronchoscopy with each patient undergoing three procedures which targets different lobes of the lung 3 weeks apart. Studies have demonstrated improved symptom control allowing discontinuation of oral steroids in some patients as well as reductions in exacerbations, hospitalizations and use of rescue medications. No development of airway strictures or bronchiectasis, and regeneration of normal epithelium after BT has been observed. At present, it remains unclear if BT benefits all asthma phenotypes or if BT has any effect on airway inflammation and remodeling. The hypothesis of this study is that bronchial thermoplasty is likely to benefit all severe asthma phenotypes, and achieves this by exerting an effect on airway inflammation and remodelling. The specific aims of the study are: 1) to better define the asthma phenotype who will benefit from BT by microarray and gene expression profiling; 2) to study effects of BT on airway inflammation; 3) to define its role in the overall asthma management algorithm

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Bronchial Thermoplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bronchial Thermoplasty
Arm Type
Other
Arm Description
Bronchial thermoplasty
Intervention Type
Procedure
Intervention Name(s)
Bronchial Thermoplasty
Intervention Description
Bronchial thermoplasty
Primary Outcome Measure Information:
Title
Asthma Control Test (ACT) score
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Percentage of symptom-free days
Time Frame
Up to 2 years
Title
Number of adverse events
Time Frame
Up to 2 years
Title
Peak Expiratory Flow (PEF)
Time Frame
Up to 2 years
Title
Exhaled nitric oxide (NO)
Time Frame
Up to 2 years
Title
Forced Expiratory Volume in 1 Second (FEV1)
Time Frame
Up to 2 years
Title
Non-contrast Computed Tomography (CT) scan of the thorax
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females between 21-65 years of age Poorly controlled severe persistent asthma (ACT score < 20) despite high-dose inhaled steroids (>500 mcg fluticasone/day or >800 mcg budesonide/day) in combination with inhaled long-acting Beta-2 agonist and/or anticholinergic agent. Other drugs include leukotriene modifiers, omalizumab (if used for at least 1 year prior), and oral corticosteroids 10mg/day or less Stopped smoking for > 1 year and <10 pack-years Stable maintenance asthma medications for 4 weeks Pre-bronchodilator FEV1 >60% predicted Exclusion Criteria: Males and females <21 and >65 years of age Presence of pacemaker, internal defibrillator, or other implantable electronic devices Known sensitivity to medications required to perform bronchoscopy, including lignocaine and benzodiazepines Patients previously treated with Bronchial Thermoplasty (BT) Use of immunosuppressant (excluding oral steroids) Increased risk of adverse events associated with bronchoscopy or anesthesia (including pregnancy, uncontrolled coronary artery disease, acute or chronic renal failure, and uncontrolled hypertension) Inability to cease antiplatelet or anticoagulant therapy prior to procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kay Leong Khoo, MD
Organizational Affiliation
National University Hospital, Singapore
Official's Role
Principal Investigator
Facility Information:
Facility Name
National University Hospital
City
Singapore
Country
Singapore
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kay Leong Khoo, MD
Phone
65-67795555
Email
khoo_kay_leong@nuhs.edu.sg
First Name & Middle Initial & Last Name & Degree
Kay Leong Khoo, MD
First Name & Middle Initial & Last Name & Degree
Pyng Lee, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
13102418
Citation
HOUSTON JC, DE NAVASQUEZ S, TROUNCE JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax. 1953 Sep;8(3):207-13. doi: 10.1136/thx.8.3.207. No abstract available.
Results Reference
background
PubMed Identifier
12867228
Citation
Kuyper LM, Pare PD, Hogg JC, Lambert RK, Ionescu D, Woods R, Bai TR. Characterization of airway plugging in fatal asthma. Am J Med. 2003 Jul;115(1):6-11. doi: 10.1016/s0002-9343(03)00241-9.
Results Reference
background
PubMed Identifier
1986670
Citation
Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis. 1991 Jan;143(1):138-43. doi: 10.1164/ajrccm/143.1.138.
Results Reference
background
PubMed Identifier
3624696
Citation
Hogg JC. Varieties of airway narrowing in severe and fatal asthma. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):417-9. doi: 10.1016/0091-6749(87)90065-0. No abstract available.
Results Reference
background
PubMed Identifier
8368644
Citation
Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, Hunt LW, Gleich GJ. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis. 1993 Sep;148(3):713-9. doi: 10.1164/ajrccm/148.3.713.
Results Reference
background
PubMed Identifier
21835905
Citation
Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2012 Mar;141(3):599-606. doi: 10.1378/chest.11-0741. Epub 2011 Aug 11.
Results Reference
background
PubMed Identifier
18480428
Citation
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224. doi: 10.1164/rccm.200711-1754OC. Epub 2008 May 14.
Results Reference
background
PubMed Identifier
22077066
Citation
Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012 Apr 1;185(7):709-14. doi: 10.1164/rccm.201105-0883CI. Epub 2011 Nov 10.
Results Reference
background
PubMed Identifier
22878625
Citation
Lee P, Khoo KL. A review of current bronchoscopic interventions for obstructive airway diseases. Ther Adv Respir Dis. 2012 Oct;6(5):297-307. doi: 10.1177/1753465812455448. Epub 2012 Aug 9.
Results Reference
background
PubMed Identifier
11181995
Citation
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng ML, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers YH, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint NN, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril JF, Guigo R, Campbell MJ, Sjolander KV, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang YH, Coyne M, Dahlke C, Deslattes Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X. The sequence of the human genome. Science. 2001 Feb 16;291(5507):1304-51. doi: 10.1126/science.1058040. Erratum In: Science 2001 Jun 5;292(5523):1838.
Results Reference
background
PubMed Identifier
21471098
Citation
Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, McDonald VM, Sim A, Gibson PG. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1633-43. doi: 10.1164/rccm.201010-1623OC. Epub 2011 Mar 18.
Results Reference
background
PubMed Identifier
11395414
Citation
Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem. 2001;70:437-73. doi: 10.1146/annurev.biochem.70.1.437.
Results Reference
background
PubMed Identifier
11431033
Citation
Naaby-Hansen S, Waterfield MD, Cramer R. Proteomics--post-genomic cartography to understand gene function. Trends Pharmacol Sci. 2001 Jul;22(7):376-84. doi: 10.1016/s0165-6147(00)01663-1.
Results Reference
background
PubMed Identifier
15996009
Citation
Zhao J, Zhu H, Wong CH, Leung KY, Wong WS. Increased lungkine and chitinase levels in allergic airway inflammation: a proteomics approach. Proteomics. 2005 Jul;5(11):2799-807. doi: 10.1002/pmic.200401169.
Results Reference
background
PubMed Identifier
18594147
Citation
Wong WS, Zhao J. Proteome analysis of chronically inflamed lungs in a mouse chronic asthma model. Int Arch Allergy Immunol. 2008;147(3):179-89. doi: 10.1159/000142040. Epub 2008 Jul 2.
Results Reference
background
PubMed Identifier
21751807
Citation
Quesada Calvo F, Fillet M, Renaut J, Crahay C, Gueders M, Hacha J, Paulissen G, Foidart JM, Noel A, Rocks N, Leprince P, Cataldo D. Potential therapeutic target discovery by 2D-DIGE proteomic analysis in mouse models of asthma. J Proteome Res. 2011 Sep 2;10(9):4291-301. doi: 10.1021/pr200494n. Epub 2011 Aug 3.
Results Reference
background
PubMed Identifier
20665705
Citation
Liao W, Goh FY, Betts RJ, Kemeny DM, Tam J, Bay BH, Wong WS. A novel anti-apoptotic role for apolipoprotein L2 in IFN-gamma-induced cytotoxicity in human bronchial epithelial cells. J Cell Physiol. 2011 Feb;226(2):397-406. doi: 10.1002/jcp.22345.
Results Reference
background
PubMed Identifier
20371397
Citation
Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG; National Institutes of Health/National Heart, Lung, and Blood Institute's Severe Asthma Research Program. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol. 2010 Apr;125(4):851-857.e18. doi: 10.1016/j.jaci.2010.01.048.
Results Reference
background

Learn more about this trial

Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype

We'll reach out to this number within 24 hrs